Loading…
Product type
Rituximab biosimilar API is a biotechnologically derived active pharmaceutical ingredient used primarily in the treatment of certain types of cancers and autoimmune diseases. It is a monoclonal antibody that targets the CD20 protein found on the surface of B cells, leading to their destruction. This biosimilar version is developed to be highly similar to the reference product, ensuring comparable efficacy and safety profiles.
| Formulation | Lyophilized powder for reconstitution |
| Purity | Typically greater than 95% |
| Storage conditions | Store at -20°C or lower |
| Shelf life | 24 months from the date of manufacture |
| Regulatory status | Must comply with local and international guidelines |
When selecting a rituximab biosimilar API, buyers should consider the specific formulation required for their applications, including any necessary excipients. It is important to specify the desired purity levels, storage conditions, and shelf life. Additionally, ensure that the product meets relevant regulatory standards and certifications, and inquire about batch sizes and lead times for production.
Get quotes for Rituximab Biosimilar API
Tell us your requirement — quantity, specs and timeline — and our team sources verified manufacturers and brings you the best quote.
A biosimilar API is a biologic medical product highly similar to an already approved reference product, with no clinically meaningful differences.
It is typically administered via intravenous infusion after reconstitution.
It is commonly used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders like rheumatoid arthritis.
Look for high purity, compliance with regulatory standards, and stability under specified storage conditions.
Many suppliers offer samples for testing, so it’s advisable to request one to evaluate the product.
Yes, ensure that the API complies with relevant GMP standards and any local regulatory requirements.